

Enantioselective synthesis of pyrazolone α -aminonitrile derivatives via an organocatalytic Strecker reaction

Suruchi Mahajan,^{†a} Pankaj Chauhan,^{†a} Uğur Kaya,^a Kristina Deckers,^a Kari Rissanen^b and Dieter Enders^{*a}

Contents

General Methods and Materials	1
General Procedure	1-3
Analytical Data	3-17
NMR Spectra	18-50
HPLC Data	51-66


General Methods and Materials:

All reactions were performed in oven-dried glassware. Analytical TLC were carried out using SIL G-25 UV254 from Machery & Nagel and visualized with ultraviolet radiation at 254 nm. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 at ambient temperature on Varian Innova 400 or Innova 600 instruments. Chemical shifts for ^1H NMR and ^{13}C NMR spectra were reported in parts per million (ppm), with coupling constants given in Hertz (Hz). The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet and br = broad signal. Mass spectra were recorded with the spectrometer SSQ 7000 from Finnigan at 70 eV, whereas HRMS data (ESI) were collected with a ThermoFisher Scientific LTQ-Orbitrap XL apparatus. IR spectra were taken on a PerkinElmer Spectrum 100 FT-IR spectrometer. Analytical HPLC was carried out either on a Hewlett-Packard 1050 series instrument or Agilent 1100 instrument using chiral stationary phases. Analytical SFC was carried out on a Thar SFC Waters Method Station II instrument using chiral stationary phases. The diastomeric ratio was determined by the ^1H NMR and HPLC analysis of the isolated product. Optical rotation values were measured on a Perkin-Elmer 241 polarimeter. Melting points were measured on a LLG MPM-H2 melting point instrument.

Unless specified, the starting materials and reagents were purchased directly from the commercial suppliers and used without further purification. The catalysts **C1** to **C5**¹ and **C-7** to **C-8**² were synthesized using known literature procedures.

General Procedures:


General procedure for the synthesis of pyrazolone derived aryl ketimines 2a,g-p (Scheme 1): Nitrosoarene **5** (1.0 equiv.) and K_2CO_3 (0.2 equiv.) were added to a solution of pyrazolone derivative **6** (1.0 equiv.) in MeOH (0.6 M) at room temperature. The reaction mixture was then refluxed for 3 hours. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate. The organic layer was washed three times with water, once with brine and then dried over anhydrous MgSO_4 . After evaporation of ethyl acetate under reduced pressure, the crude product was purified by flash column chromatography (*n*-pentane/diethyl ether, 3:1) to afford the ketimine products **2a,g-p**.



Scheme 1


1. (a) J. P. Malerich, K. Hagihara and V. H. Rawal, *J. Am. Chem. Soc.*, **2008**, *130*, 14416; (b) Y. Zhu, J. P. Malerich and V. H. Rawal, *Angew. Chem., Int. Ed.*, **2010**, *49*, 153.
2. H. L. Yi, W. L. Tang and L. Deng, *J. Am. Chem. Soc.*, **2004**, *126*, 9906.

Procedure for the synthesis of pyrazolone-derived ketone 7 (Scheme 2): The ketimine **2a** (20 mmol) was dissolved in THF (0.13 M) and a 2.0 N HCl solution (20 mL) was added to the reaction mixture at room temperature. The progress of the reaction was monitored on TLC. After completion of the reaction, the mixture was diluted with water. The organic layer was extracted three times with dichloromethane and the combined organic layers were dried over anhydrous MgSO₄. The solvent was removed under reduced pressure and the crude product was directly purified by flash column chromatography (*n*-hexane/EtOAc, 1:1) to afford the desired product **7**.




Scheme 2

General procedure for the synthesis of pyrazolone derived aryl ketimines 2c-f (Scheme 3): A mixture of pyrazolone-derived ketone **7** (1.0 equiv.) and aniline derivative (1.0 equiv.) in EtOH (2.0 M) was refluxed for 5 hours. In the case of **2e**, *p*-TSA (30 mol%) was added as catalyst. After completion of the reaction, the solvent was removed under reduced pressure and the crude product was directly purified by flash column chromatography (*n*-pentane/diethyl ether, 3:1) to afford the desired product **2c-f**.



Scheme 3


General procedure for the synthesis of pyrazolone derived *N*-Boc ketimine 2b (Scheme 4): The *tert*-butyl(triphenylphosphoranylidene)acetate (1.1 equiv.) was added to a solution of the pyrazolone-derived ketone **7** in 1,4-dioxane (0.2 M) at room temperature and the mixture was refluxed for 3-3.5 hours. After completion of the reaction, the solvent was removed under reduced pressure and the crude product was directly purified by flash column chromatography (*n*-pentane/diethyl ether, 1:1) to afford the desired product **2b**.



Scheme 4


General procedure for the organocatalytic enantioselective Strecker synthesis of 3 and *ent*-3 (Scheme 5): In a 10 mL reaction tube equipped with a magnetic stirring bar, the imine **2** (1 equiv., 0.2 mmol), catalyst **C-2** or **C-5** (5 mol%) were stirred in dichloroethane (4.5 mL) at room temperature. After 10 minutes, trimethylsilyl cyanide **1a** (1.5 equiv. 0.45 mmol) was added and the stirring was continued for 4 days at room temperature. The crude product was

directly purified by flash column chromatography (*n*-hexane/EtOAc, 4:1) to afford the products **3** or *ent*-**3**.




Scheme 5

Procedure for the deprotection of the 4-methoxyphenyl group (Scheme 6): The α -amino nitrile *ent*-**3e** (64 mg, 0.2 mmol) was dissolved in CH₃CN/H₂O (1:1, 4 mL). Periodic acid (182 mg, 0.8 mmol, 4 equiv.) and sulfuric acid (0.4 mL) were added and the mixture was stirred until completion of the reaction in 1 h. Diethyl ether was added to the solution, the phases were separated and the aqueous phase was extracted twice with diethyl ether. The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The crude product was directly purified by flash column chromatography (*n*-hexane/EtOAc, 6:4) to afford the product **4**.




Scheme 6


Analytical data:




5-Methyl-2-phenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2a). Red solid; mp = 102–104 °C; IR (Capillary): 3060, 2287, 2084, 1937, 1664, 1587, 1488, 1412, 1360, 1297, 1132, 998, 911, 831, 744, 687 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.88–7.86 (m, 2H, ArH), 7.45–7.23 (m, 7H, ArH), 7.22–7.19 (m, 1H, ArH), 2.35 (s, 3H, CH₃); ¹³C NMR (151 MHz, CDCl₃): δ 152.7, 151.2, 150.8, 146.3, 137.7, 129.0 (2C), 128.7 (2C), 125.6, 121.8 (2C), 118.5 (2C), 118.4, 12.4; MS (EI): m/z 262.9 M⁺; HRMS Calcd for [C₁₆H₁₃N₃O + H]⁺: 264.1131, found: 264.1131.




tert-Butyl (3-methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)carbamate (2b). Orange solid; mp = 173-175 °C; IR (Capillary): 2979, 2319, 2110, 1722, 1596, 1482, 1369, 1250, 1143, 843, 759 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.84-7.82 (m, 2H, ArH), 7.42-7.40 (m, 2H, ArH), 7.24-7.21 (m, 1H, ArH), 2.28 (s, 3H, Me), 1.64 (s, 9H, *t*-Bu); ¹³C NMR (151 MHz, CDCl₃): δ 158.9, 153.9, 150.2, 150.0, 137.0, 129.1 (2C), 126.0, 118.3 (2C), 85.4, 28.1 (3C), 12.1; MS (EI): *m/z* 286.9 M⁺; HRMS Calcd for [C₁₅H₁₇N₃O₃ + Na]⁺: 310.1162, found: 310.1161.



4-((4-Fluorophenyl)imino)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2c). Red solid; mp = 98-100 °C; IR (Capillary): 3076, 2674, 2345, 2110, 1906, 1694, 1490, 1310, 1231, 1117, 1013, 840, 758, 688, 660 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.87 – 7.84 (m, 2H, ArH), 7.60 – 7.57 (m, 2H, ArH), 7.41 – 7.37 (m, 2H, ArH), 7.22 – 7.20 (m, 1H, ArH), 7.13 – 7.09 (m, 2H, ArH), 2.31 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 163.2, 152.0, 151.5, 151.1, 142.0, 137.7, 129.0 (2C), 126.1 (2C), 125.7, 118.6 (2C), 115.7 (2C), 12.4; MS (EI): *m/z* 280.9 M⁺; Elemental Analysis (CHN): calculated for [C₁₆H₁₂N₃OF]: C = 68.32%, H = 4.30%, N = 14.94%, found C = 68.15%, H = 4.52%, N = 16.63%.




4-((4-Chlorophenyl)imino)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2d). Red solid; mp = 118- 120 °C; IR (Capillary): 3470, 2972, 2287, 2089, 1887, 1732, 1587, 1484, 1368, 1214, 1084, 1018, 836, 757 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 8.1 Hz, 2H, ArH), 7.42 – 7.37 (m, 6H, ArH), 7.22 (t, *J* = 7.4 Hz, 1H, ArH), 2.33 (s, 3H, CH₃); ¹³C NMR (151 MHz, CDCl₃): δ 152.8, 151.2, 150.8, 144.5, 137.5, 134.7, 129.0 (2C), 128.9 (2C), 125.7, 123.9 (2C), 118.5 (2C), 12.4; MS (EI): *m/z* 296.8 M⁺; Elemental Analysis (CHN): calculated for [C₁₆H₁₂N₃OCl]: C = 64.54%, H = 4.06%, N = 14.11%, found C = 64.73%, H = 4.25%, N = 14.05%.




4-((4-Trifluoromethylphenyl)imino)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2e). Red solid; mp = 155-157 °C; IR (Capillary): 3081, 2653, 2295, 2176, 2111, 2060, 2015, 1926, 1893, 1702, 1592, 1492, 1416, 1309, 1155. 1106, 1058, 840, 755, 692 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.84 – 7.81 (m, 2H, ArH), 7.66 (d, *J* = 8.3 Hz, 2H, ArH), 7.40 – 7.36 (m, 2H, ArH), 7.24 – 7.18 (m, 3H, ArH), 2.34 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ


154.2, 150.7, 150.3, 149.6, 137.4, 129.2, 129.1 (2C), 126.1 (2C), 125.9, 120.0 (2C), 118.5, 118.4 (2C), 12.3; ^{19}F NMR (376 MHz, CDCl_3): δ -62.4; MS (EI): m/z 331.1 M^+ ; Elemental Analysis (CHN): calculated for $[\text{C}_{17}\text{H}_{12}\text{N}_3\text{OF}_3]$: C = 61.63%, H = 3.65%, N = 12.68%, found C = 61.63%, H = 3.64%, N = 12.69%.




4-((4-Methoxyphenyl)imino)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (2f). Red solid; mp = 111-113 °C; IR (Capillary): 2929, 2661, 2340, 2092, 1906, 1686, 1499, 1253, 1113, 1012, 837, 755 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.95 – 7.91 (m, 4H, ArH), 7.43 – 7.41 (m, 2H, ArH), 7.22 – 7.19 (m, 1H, ArH), 6.97 – 6.89 (m, 2H, ArH), 3.88 (s, 3H, OCH_3), 2.32 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 162.2, 152.4, 151.6, 148.9, 139.4, 138.0, 129.4 (2C), 129.0 (2C), 125.4, 118.7 (2C), 114.0 (2C), 55.6, 12.5; MS (EI): m/z 292.8 M^+ ; Elemental Analysis (CHN): calculated for $[\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2]$: C = 69.61%, H = 5.15%, N = 14.33%, found C = 69.58%, H = 5.16%, N = 14.41%.




5-Methyl-2-phenyl-4-(o-tolylimino)-2,4-dihydro-3H-pyrazol-3-one (2g). Red solid; mp = 71-73 °C; IR (Capillary): 3389, 2920, 2648, 2325, 2093, 1906, 1712, 1594, 1481, 1307, 1151, 1036, 843, 758 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.89 – 7.87 (m, 2H, ArH), 7.41 – 7.38 (m, 2H, ArH), 7.30 – 7.17 (m, 5H, ArH), 2.37 (s, 3H, CH_3), 2.30 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 152.2, 151.3, 150.6, 145.4, 137.7, 130.8, 129.2, 129.0 (2C), 128.6, 125.8, 125.6, 118.5, 118.4 (2C), 18.2, 12.4; MS (EI): m/z 276.9 M^+ ; HRMS Calcd for $[\text{C}_{17}\text{H}_{15}\text{N}_3\text{O} + \text{Na}]^+$: 300.1107, found: 300.1107.




2-(4-Chlorophenyl)-5-methyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2h). Red solid (83 mg, 95%); mp = 121-123 °C; IR (Capillary): 3461, 2993, 2678, 2338, 2093, 1902, 1716, 1577, 1479, 1305, 1105, 994, 820 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.85 – 7.83 (m, 2H, ArH), 7.44 – 7.31 (m, 7H, ArH), 2.32 (s, 3H, CH_3); ^{13}C NMR (101 MHz, CDCl_3): δ 152.2, 151.2, 151.1, 146.2, 136.3, 129.1 (2C), 129.0, 128.7 (2C), 122.03, 122.01, 119.4 (2C), 118.8, 12.4; MS (EI): m/z 296.8 M^+ ; HRMS Calcd for $[\text{C}_{16}\text{H}_{12}\text{N}_3\text{OCl} + \text{H}]^+$: 298.0742, found: 298.0742.




2-(2-Chlorophenyl)-5-methyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2i). Red solid; mp = 119-120 °C; IR (Capillary): 3460, 2999, 2332, 2090, 1904, 1737, 1366, 1216, 1061, 885, 739 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.51 – 7.47 (m, 3H, ArH), 7.44 – 7.39 (m, 3H, ArH), 7.35 – 7.31 (m, 3H, ArH), 2.33 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 151.9, 151.4, 150.9, 146.1, 130.7, 130.1, 129.3, 129.1, 128.7 (2C), 128.6, 127.7, 122.9 (2C), 118.9, 12.5; MS (EI): m/z 296.7 M^+ ; Elemental Analysis (CHN): calculated for $[\text{C}_{16}\text{H}_{12}\text{N}_3\text{OCl}]$: C = 64.54%, H = 4.06%, N = 14.11%, found C = 64.52%, H = 4.01%, N = 14.32%.




5-Methyl-4-(phenylimino)-2-(p-tolyl)-2,4-dihydro-3H-pyrazol-3-one (2j). Red solid; mp = 75-77 °C; IR (Capillary): 3354, 2934, 2702, 2339, 2092, 1907, 1690, 1497, 1306, 1129, 993, 774, 683 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.75 (d, J = 8.5 Hz, 2H, ArH), 7.44 – 7.42 (m, 2H, ArH), 7.38 – 7.36 (m, 2H, ArH), 7.34 – 7.31 (m, 1H, ArH), 7.20 – 7.19 (m, 2H, ArH), 2.35 (s, 3H, CH_3), 2.33 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 152.8, 151.1, 150.6, 146.3, 135.3, 135.2, 129.5(2C), 129.1, 128.7(2C), 128.6, 121.8, 118.4 (2C), 21.1, 12.4; MS (EI): m/z 276.9 M^+ ; HRMS Calcd for $[\text{C}_{17}\text{H}_{15}\text{N}_3\text{O} + \text{Na}]^+$: 300.1107, found: 300.1107.




2,5-Dimethyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2k). Red wax; IR (CDCl_3): 3339, 2932, 2666, 2340, 2094, 1906, 1705, 1440, 1307, 1218, 1056, 935, 735 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.41 – 7.24 (m, 5H, ArH), 3.28 (s, 3H, CH_3), 2.20 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 153.0, 152.7, 149.1, 146.3, 128.7 (2C), 122.1 (2C), 115.3, 31.7, 12.2; MS (EI): m/z 201.1 M^+ ; HRMS Calcd for $[\text{C}_{11}\text{H}_{11}\text{N}_3\text{O} + \text{Na}]^+$: 224.0794, found: 224.0794.




5-Ethyl-2-phenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2l). Red solid; mp = 94-96 °C; IR (Capillary): 3460, 2970, 2663, 2336, 2094, 1912, 1728, 1589, 1479, 1341, 1225, 1117, 1037, 919, 836, 755 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): 7.92 – 7.90 (m, 2H, ArH), 7.45 – 7.32 (m, 6H, ArH), 7.22 – 7.20 (m, 2H, ArH), 2.76 (q, *J* = 7.5 Hz, 2H, CH₂CH₃), 1.40 (t, *J* = 7.5 Hz, 3H, CH₂CH₃); ¹³C NMR (151 MHz, CDCl₃): δ 154.6, 152.3, 151.3, 146.4, 137.7, 129.0 (2C), 128.7 (2C), 128.5, 125.5, 121.7, 118.4 (2C), 118.3, 20.2, 10.6; MS (EI): *m/z* 276.8 M⁺; HRMS Calcd for [C₁₇H₁₅N₃O + Na]⁺: 300.1107, found: 300.1109.



2-Phenyl-4-(phenylimino)-5-propyl-2,4-dihydro-3H-pyrazol-3-one (2m). Red Solid; mp = 55-58 °C; IR (Capillary): 3351, 2944, 2338, 2092, 1905, 1703, 102, 1478, 1314, 1101, 894, 753 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): 7.89 – 7.87 (m, 2H, ArH), 7.44 – 7.38 (m, 4H, ArH), 7.35 – 7.30 (m, 3H, ArH), 7.22 – 7.19 (m, 1H, ArH), 2.71 – 2.69 (m, 2H, CH₂CH₂CH₃), 1.89 – 1.83 (m, 2H, CH₂CH₂CH₃), 1.09 (t, *J* = 7.4 Hz, 3H, CH₂CH₂CH₃); ¹³C NMR (151 MHz, CDCl₃): δ 153.7, 152.5, 151.26, 146.5, 137.7, 129.0 (2C), 128.7 (2C), 128.6, 125.6, 121.6 (2C), 118.5 (2C), 28.6, 20.1, 14.1; MS (EI): *m/z* 290.9 M⁺; Elemental Analysis (CHN): calculated for [C₁₈H₁₇N₃O]: C = 74.20%, H = 5.88%, N = 14.42%, found C = 74.03%, H = 5.70%, N = 14.44%.




5-Isopropyl-2-phenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2n). Red solid; mp = 77-79 °C; IR (Capillary): 3398, 2959, 2707, 2340, 2093, 1709, 1593, 1467, 1334, 1256, 1102, 977, 835, 747, 685 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.92 – 7.91 (m, 2H, ArH), 7.45 – 7.39 (m, 4H, ArH), 7.34 – 7.31 (m, 3H, ArH), 7.22 – 7.19 (m, 1H, ArH), 3.22 – 3.18 (m, 1H, CH(CH₃)₂), 1.42 (d, *J* = 7.0 Hz, 6H, CH(CH₃)₂); ¹³C NMR (151 MHz, CDCl₃): δ 157.5, 152.0, 151.3, 146.5, 137.8, 129.0 (2C), 128.7 (2C), 128.4, 125.5, 121.4 (2C), 118.4 (2C), 27.1, 20.1 (2C); MS (EI): *m/z* 290.9 M⁺; HRMS Calcd for [C₁₈H₁₇N₃O + Na]⁺: 314.1264, found: 314.1264.




5-(tert-Butyl)-2-phenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2o). Red solid; mp = 95-97 °C; IR (Capillary): 2957, 2340, 2095, 1925, 1717, 1590, 1479, 1375, 1304, 1213, 1108, 963, 839, 689 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.93 – 7.91 (m, 2H, ArH), 7.45 – 7.39 (m, 4H, ArH), 7.31 7.29 (m, 1H, ArH), 7.24 – 7.19 (m, 3H, ArH), 1.51 (s, 9H,


$\text{C}(\text{CH}_3)_3$; ^{13}C NMR (151 MHz, CDCl_3): δ 158.4, 152.0, 150.8, 146.7, 137.7, 128.9 (2C), 128.7 (2C), 127.8, 125.4, 120.3 (2C), 118.3 (2C), 35.1, 28.1(3C); MS (EI): m/z 304.9 M^+ ; HRMS Calcd for $[\text{C}_{19}\text{H}_{19}\text{N}_3\text{O} + \text{H}]^+$: 306.1601, found: 306.1602.




2,5-Diphenyl-4-(phenylimino)-2,4-dihydro-3H-pyrazol-3-one (2p). Red solid; mp = 176–178 °C; IR (Capillary): 3449, 3026, 2682, 2338, 2092, 1896, 1714, 1592, 1482, 1399, 1307, 1142, 925, 838, 687 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 8.32 – 8.30 (m, 2H, ArH), 7.99 – 7.97 (m, 2H, ArH), 7.51 – 7.42 (m, 7H, ArH), 7.35 – 7.21 (m, 3H, ArH), 7.26 – 7.23 (m, 1H, ArH); ^{13}C NMR (151 MHz, CDCl_3): δ 152.1, 150.7, 147.1, 146.9, 137.6, 130.8, 129.0 (2C), 128.8 (3C), 128.7 (2C), 128.2, 128.1 (2C), 125.9, 120.6 (2C), 118.7 (2C); MS (EI): m/z 324.8 M^+ ; Elemental Analysis (CHN): Calcd for $[\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}]$: C = 77.52%, H = 4.65%, N = 12.91%, found C = 77.69%, H = 4.71%, N = 13.08%.




3-Methyl-1-phenyl-1H-pyrazole-4,5-dione (7). Red solid; mp = 119–121 °C; IR (Capillary): 3083, 2078, 1765, 1722, 1591, 1492, 1434, 1416, 1370, 1279, 1151, 1086, 1039, 972, 913, 849, 763, 689 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.84 – 7.82 (m, 2H, ArH), 7.44 – 7.40 (m, 2H, ArH), 7.26 – 7.22 (m, 1H, ArH), 2.18 (s, 3H, CH_3); ^{13}C NMR (101 MHz, CDCl_3): δ 184.6, 149.2, 144.5, 137.0, 129.3 (2C), 126.3, 117.8 (2C), 11.1; MS (EI): m/z 188.1 M^+ ; HRMS Calcd for $[\text{C}_{10}\text{H}_8\text{N}_2\text{O}_2]^+$: 188.0580, found: 188.0583.




(R)-3-Methyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3a). Reddish brown wax (83 mg, 95%); $[\alpha]_{\text{D}}^{24} = -11.5$ ($c = 0.6$, CH_2Cl_2); 95.5:4.5 *er*; HPLC: tR 11.08 min (major), 12.44 min (minor), 230 nm, *n*-heptane/*i*-PrOH, 97:3, 0.7 mL/min, Chiralpak IC column; IR (CHCl_3): 3329, 2916, 2314, 2098, 1732, 1467, 1369, 1222, 747 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.85 – 7.83 (m, 2H, ArH), 7.46 – 7.44 (m, 2H, ArH), 7.30 – 7.26 (m, 1H, ArH), 7.22 – 7.20 (m, 2H, ArH), 6.96 (t, $J = 7.4$ Hz, 1H, ArH), 6.70 – 6.69 (m, 2H, ArH), 4.71 (s, 1H, NH), 2.35 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 164.7, 154.7, 141.9, 136.9, 129.9 (2C), 129.3 (2C), 126.6, 122.7, 119.2 (2C), 116.6 (2C), 112.4, 62.4, 14.5; MS (EI): m/z 289.9 M^+ ; HRMS Calcd for $[\text{C}_{17}\text{H}_{14}\text{N}_4\text{O} + \text{Na}]^+$: 313.1060, found: 313.1061.




(S)-3-Methyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (*ent*-3a). Reddish brown wax (75 mg, 86%); 93.9:6.1 *er*; HPLC: tR 11.21 min (minor), 12.51 min (major), 230 nm, *n*-heptane/*i*-PrOH, 97:3, 0.7 mL/min, Chiralpak IC column.




***tert*-Butyl (*R*)-(4-cyano-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)carbamate (3b).** White Solid (93 mg, 83%); mp = 150 – 152 °C [α]_D²⁴ = –10.0 (*c* = 0.5, CHCl₃); 62:38 *er*; HPLC: tR 7.73 min (minor), 8.23 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 0.5 mL/min, Chiralpak IA column; IR (Capillary): 3306, 2980, 2335, 2106, 1715, 1599, 1498, 1364, 1278, 1155, 880, 753 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 8.1 Hz, 2H, ArH), 7.44 – 7.41 (m, 2H, ArH), 7.26 – 7.24 (m, 1H), 5.98 (s, 1H, NH), 2.30 (s, 3H, CH₃), 1.39 (br s, 9H, *t*-Bu); ¹³C NMR (151 MHz, CDCl₃): δ 164.1, 153.1, 137.2, 129.2 (2C), 126.3 (2C), 119.2 (2C), 111.1, 83.6, 58.9, 28.1 (3C), 13.7; MS (EI): *m/z* 314.2 M⁺; HRMS Calcd for [C₁₆H₁₈N₄O₃ + Na]⁺: 337.1271, found: 337.1269.




(*R*)-4-((4-Fluorophenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (3c). Yellowish brown wax (69 mg, 75%); [α]_D²⁴ = –18.0 (*c* = 0.5, CH₂Cl₂); 97.0:3.0 *er*; HPLC: tR 8.27 min (minor), 15.32 min (major), 230 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak AD column; IR (CHCl₃): 3343, 3052, 2257, 2090, 1724, 1600, 1501, 1363, 1227, 1115, 783 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.79 – 7.76 (m, 2H, ArH), 7.44 – 7.40 (m, 2H, ArH), 7.28 – 7.23 (m, 1H, ArH), 6.93 – 6.89 (m, 2H, ArH), 6.77 – 6.74 (m, 2H), 4.52 (s, 1H, NH), 2.33 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 164.8, 159.2, 154.3, 137.6, 136.8, 129.3 (2C), 126.6, 120.3 (2C), 119.2 (2C), 116.6 (2C), 112.4, 63.0, 14.5; MS (EI): *m/z* 308.0 M⁺; HRMS Calcd for [C₁₇H₁₃N₄OF + Na]⁺: 331.0966, found: 331.0966.




(S)-4-((4-Fluorophenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3c). Yellowish brown wax (64 mg, 69%); 96.9:3.1 *er*; HPLC: tR 8.27 min (major), 15.33 min (minor), 230 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak AD column.



(R)-4-((4-Chlorophenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (3d). Light brown wax (78 mg, 80%); $[\alpha]_D^{24} = -4.0$ ($c = 0.5$, CH_2Cl_2); 94.4:5.6 *er*; HPLC: tR 6.35 min (minor), 13.32 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3305, 2919, 2318, 2100, 1728, 1599, 1473, 1371, 1180, 1089, 812 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.84 – 7.72 (m, 2H, ArH), 7.47 – 7.44 (m, 2H, ArH), 7.31 – 7.28 (m, 1H, ArH), 7.15 – 7.14 (m, 2H, ArH), 6.62 – 6.60 (m, 2H, ArH), 4.87 (s, 1H, NH), 2.34 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 164.6, 154.5, 140.5, 136.8, 129.8 (2C), 129.3 (2C), 127.8, 126.7, 119.2 (2C), 117.8 (2C), 112.1, 62.3, 14.4; MS (EI): m/z 323.9 M^+ , HRMS Calcd for $[\text{C}_{17}\text{H}_{13}\text{N}_4\text{OCl} + \text{Na}]^+$: 347.0670, found: 347.0671.




(S)-4-((4-Chlorophenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3d). Light brown wax (77 mg, 79%); 94.4:5.6 *er*; HPLC: tR 6.35 min (major), 13.35 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-4-((4-Trifluoromethylphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (3e). Light brown wax (88 mg, 82%); $[\alpha]_D^{24} = -15.0$ ($c = 0.4$, CH_2Cl_2); 85.5:15.5 *er*; HPLC: tR 10.35 min (major), 13.81 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 9:1, 1.0 mL/min, Chiralpak IA column; IR (CHCl_3): 3351, 2324, 2085, 1722, 1615,


1530, 1495, 1362, 1321, 1262, 1160, 1100, 1065, 1011, 941, 908, 827, 755, 688 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.87 – 7.84 (m, 2H, ArH), 7.48 – 7.44 (m, 2H, ArH), 7.38 (d, J = 8.4 Hz, 2H, ArH), 7.32 – 7.28 (m, 1H, ArH), 6.59 (d, J = 8.4 Hz, 2H, ArH), 5.38 (s, 1H, NH), 2.33 (s, 3H, CH_3); ^{13}C NMR (101 MHz, CDCl_3): δ 164.4, 154.5, 144.9, 136.8, 129.4 (2C), 127.2 (2C), 126.9, 124.2, 123.7, 119.2 (2C), 114.7, 114.4, 111.7, 61.7, 14.2; MS (EI): m/z 358.4 M^+ , HRMS Calcd for $[\text{C}_{18}\text{H}_{13}\text{N}_4\text{OF}_3 + \text{K}]^+$: 397.0673, found: 397.0607.




(S)-4-((4-Trifluoromethylphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (*ent*-3e). Light brown wax (86 mg, 80%); 89:11 *er*; HPLC: tR 10.31 min (minor), 13.75 min (major), 254 nm, *n*-heptane/*i*-PrOH, 9:1, 1.0 mL/min, Chiralpak IA column.




(R)-4-((4-Methoxyphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (3f). Brown wax (58 mg, 60%); $[\alpha]_{\text{D}}^{24} = -16.7$ (c = 0.6, CH_2Cl_2); 97.6:2.4 *er*; HPLC: tR 8.05 min (minor), 17.36 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3276, 2910, 2343, 2088, 1731, 1475, 1205, 1056, 789 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.79 – 7.77 (m, 2H, ArH), 7.43–7.41 (m, 2H, ArH), 7.26–7.24 (m, 1H, ArH), 6.85 (d, J = 9.0 Hz, 2H, ArH), 6.77 (d, J = 8.9 Hz, 2H, ArH), 4.35 (s, 1H, NH), 3.73 (s, 3H, OCH_3), 2.33 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 165.2, 156.7, 154.5, 136.8, 134.4, 129.2 (2C), 126.5, 122.2 (2C), 119.2 (2C), 114.9 (2C), 112.7, 63.6, 55.6, 14.7; MS (EI): m/z 319.9 M^+ ; HRMS Calcd for $[\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}_2 + \text{Na}]^+$: 343.1165, found: 343.1166.




(S)-4-((4-Methoxyphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (*ent*-3f). Brown wax (57 mg, 59%); 96.4:3.6 *er*; HPLC: tR 8.07 min (major), 17.32 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-4-((2-Methylphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (3g). Brown wax (35 mg, 38%); $[\alpha]_D^{24} = -26.7$ ($c = 0.6$, CH_2Cl_2); 93.5:6.5 *er*; HPLC: tR 5.27 min (minor), 6.37 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3325, 2969, 2334, 2098, 1737, 1600, 1365, 1216, 1053, 906, 750 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.97 – 7.85 (m, 2H, ArH), 7.47 – 7.44 (m, 2H, ArH), 7.30 – 7.27 (m, 1H, ArH), 7.15 (d, $J = 7.2$ Hz, 1H, ArH), 7.05 – 7.02 (m, 1H, ArH), 6.89 – 6.86 (m, 1H, ArH), 6.44 (dd, $J = 8.0, 1.1$ Hz, 1H, ArH), 4.41 (s, 1H, NH), 2.32 (s, 3H, CH_3), 2.29 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 164.8, 154.8, 140.2, 137.0, 131.4, 129.3 (2C), 127.6, 126.6, 125.9, 122.3, 119.2 (2C), 113.2, 112.6, 62.3, 17.7, 14.5; MS (EI): m/z 303.9 M^+ ; HRMS Calcd for $[\text{C}_{18}\text{H}_{16}\text{N}_4\text{O} + \text{Na}]^+$: 327.1216, found: 327.1219.




(S)-4-((2-Methylphenyl)amino)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3g). Brown wax (34 mg, 37%); 92.0:8.0 *er*; HPLC: tR 5.27 min (major), 6.37 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-1-(4-Chlorophenyl)-3-methyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3h). Light brown solid (76 mg, 78%); mp = 131-134 $^{\circ}\text{C}$; $[\alpha]_D^{24} = -8.2$ ($c = 0.6$, CH_2Cl_2); 97.5:2.5 *er*; HPLC: 8.74 min (minor), tR 26.88 min (major), 214 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, ChiralCel AD column; IR (CHCl_3): 3322, 3040, 2320, 2061, 1717, 1605, 1491, 1356, 1254, 1157, 1089, 1011, 830, 751 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.82 – 7.79 (m, 2H, ArH), 7.41 – 7.39 (m, 2H, ArH), 7.22 – 7.20 (m, 2H, ArH), 6.98 – 6.96 (m, 1H, ArH), 6.69 – 6.67 (m, 2H, ArH), 4.64 (s, 1H, NH), 2.35 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 164.6, 155.1, 141.8, 135.5, 131.8, 130.0 (2C), 129.4 (2C), 122.9, 120.2 (2C), 116.7 (2C), 112.2, 62.4, 14.5; MS (EI): m/z 323.9 M^+ , HRMS Calcd for $[\text{C}_{17}\text{H}_{13}\text{N}_4\text{OCl} + \text{H}]^+$: 325.0851, found: 325.0846.




(S)-1-(4-Chlorophenyl)-3-methyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (*ent*-3h). Light brown solid (76 mg, 78%); 97.0:3.0 *er*; HPLC: tR 8.70 min (major), 26.63 min (minor), 214 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-1-(2-Chlorophenyl)-3-methyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3i). White Solid (85 mg, 87%); mp = 128-130 °C; $[\alpha]_D^{24} = +15.0$ (c = 1.0, CH₂Cl₂); 97:3 *er*; HPLC: tR 3.14 min (major), 3.70 min (minor), 230 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak IC column; IR (CHCl₃): 3330, 3006, 2313, 2105, 1739, 1600, 1485, 1368, 1219, 1075, 864, 746 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.52 – 7.49 (m, 1H, ArH), 7.39 – 7.32 (m, 3H, ArH), 7.24 – 7.20 (m, 2H, ArH), 7.00 – 6.98 (m, 1H, ArH), 6.79 – 6.77 (m, 2H, ArH), 4.68 (s, 1H, NH), 2.32 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 165.5, 154.6, 141.9, 133.3, 132.0, 130.9, 130.8, 129.8 (2C), 128.6, 127.8, 122.9, 117.2 (2C), 112.3, 61.2, 14.4; MS (EI): *m/z* 323.9 M⁺; Elemental Analysis (CHN): calculated for [C₁₇H₁₃N₄OCl]: C = 62.87%, H = 4.03%, N = 17.25%, found C = 62.87%, H = 3.96%, N = 17.29%.




(R)-1-(2-Chlorophenyl)-3-methyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (*ent*-3i). White solid (85 mg, 87%); 96:4 *er*; HPLC: tR 3.14 min (minor), 3.70 min (major), 230 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak IC column.




(R)-3-Methyl-5-oxo-4-(phenylamino)-1-(p-tolyl)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3j). Reddish brown wax (72 mg, 79%); $[\alpha]_D^{24} = -18.0$ ($c = 1.0$, CH_2Cl_2); 97:3 *er*; HPLC: tR 11.86 min (minor), 43.87 min (major), 230 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, ChiralCel AD column; IR (CHCl_3): 3319, 2929, 2312, 2088, 1715, 1603, 1505, 1358, 1271, 1139, 815, 749, 690 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.72 – 7.70 (m, 2H, ArH), 7.26 – 7.24 (m, 2H, ArH), 7.21 – 7.18 (m, 2H, ArH), 6.95 (t, $J = 7.5$ Hz, 1H, ArH), 6.69 – 6.67 (m, 2H, ArH), 4.78 (s, 1H, NH), 2.38 (s, 3H, CH_3), 2.34 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 164.6, 154.6, 142.0, 136.5, 134.5, 129.8 (2C), 129.7 (2C), 122.5, 119.3 (2C), 116.5 (2C), 112.4, 62.3, 21.1, 14.4; MS (ESI): m/z 303.9 M^+ ; HRMS Calcd for $[\text{C}_{18}\text{H}_{16}\text{N}_4\text{O} + \text{Na}]^+$: 327.1216, found: 327.1218.




(S)-3-Methyl-5-oxo-4-(phenylamino)-1-(p-tolyl)-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3j). Reddish brown wax (68 mg, 75%); 96:4 *er*; HPLC: tR 11.84 min (major), 43.18 min (minor), 230 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-1,3-Dimethyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3k). Brown wax (63 mg, 92%); $[\alpha]_D^{24} = -34.9$ ($c = 0.6$, CH_2Cl_2); 96.5:3.5 *er*; HPLC: tR 4.76 min (minor), 5.86 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3369, 3013, 2277, 2088, 1725, 1601, 1493, 1375, 1221, 1034, 920, 746 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 7.22 – 7.20 (m, 2H, ArH), 6.99 – 6.92 (m, 1H, ArH), 6.65 – 6.63 (m, 2H), 4.59 (s, 1H, NH), 3.37 (s, 3H, N- CH_3), 2.22 (s, 3H, CH_3); ^{13}C NMR (151 MHz, CDCl_3): δ 166.5, 153.8, 142.0, 129.7 (2C), 122.3, 116.3 (2C), 112.3, 60.6, 32.3, 14.2; MS (EI): m/z 228.0 M^+ ; Elemental Analysis (CHN): calculated for $[\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}]$: C = 63.15%, H = 5.30%, N = 24.55%, found C = 63.09%, H = 5.16%, N = 24.47%.




(S)-1,3-Dimethyl-5-oxo-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3k). Brown wax (63 mg, 92%); 97.5:2.5 *er*; HPLC: tR 4.77 min (major), 5.86 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.



(R)-3-Ethyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3l). Brown wax (74 mg, 81%); $[\alpha]_D^{24} = -4.0$ ($c = 0.5$, CH_2Cl_2); 96.5:3.5 *er*; HPLC: tR 8.03 min (minor), 21.64 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3316, 2929, 2102, 1724, 1600, 1494, 1349, 1207, 1051, 909, 833, 747, 686 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.88 – 7.85 (m, 2H, ArH), 7.46 – 7.42 (m, 2H, ArH), 7.29 – 2.27 m, 1H, ArH), 7.19 – 7.15 (m, 2H, ArH), 6.94 – 6.91 (m, 1H, ArH), 6.64 – 6.62 (m, 2H, ArH), 4.82 (s, 1H, NH), 2.75 – 2.60 (m, 2H, CH_2CH_3), 1.36 (t, $J = 7.3$ Hz, 3H, CH_2CH_3); ^{13}C NMR (101 MHz, CDCl_3): δ 165.0, 158.8, 142.1, 137.1, 129.8 (2C), 129.2 (2C), 126.5, 122.4, 119.2 (2C), 116.2 (2C), 112.6, 62.2, 22.2, 9.4; MS (EI): m/z 303.9 M^+ ; Elemental Analysis (CHN): calculated for $[\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}]$: C = 71.04%, H = 5.30%, N = 18.41%, found C = 70.93%, H = 5.29%, N = 18.53%.




(S)-3-Ethyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3l). Brown wax (72 mg, 79%); 95.5:5.5 *er*; HPLC: tR 8.02 min (major), 21.65 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-3-*n*-Propyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3m). Brown wax (72 mg, 75%); $[\alpha]_D^{24} = -26.0$ ($c = 0.5$, CH_2Cl_2); 98:2 *er*; HPLC: tR 9.04 min (minor), 21.19 min (major), 230 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak AD column; IR (CHCl_3): 3351, 2955, 2329, 2100, 1730, 1598, 1493, 1355, 1219, 1111, 885, 748 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.85 (d, $J = 8.1$ Hz, 2H, ArH), 7.46 – 7.42 (m, 2H, ArH), 7.28 – 7.24 (m, 1H, ArH), 7.20 – 7.15 (m, 2H, ArH), 6.92 (t, $J = 7.4$ Hz, 1H, ArH), 6.63 – 6.61 (m, 2H, ArH), 4.78 (s, 1H, NH), 2.69 – 2.51 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.80 – 1.82


(m, 2H, CH₂CH₂CH₃), 1.05 (t, J = 7.3 Hz, 3H CH₂CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 164.9, 157.8, 142.1, 137.10, 129.8 (2C), 129.2 (2C), 126.5, 122.4, 119.2 (2C), 116.2 (2C), 112.6, 62.2, 30.5, 18.8, 13.8.; MS (EI): m/z 318.0 M⁺; HRMS Calcd for [C₁₉H₁₈N₄O + Na]⁺: 341.1373, found: 341.1372.




(S)-3-*n*-Propyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3m). Brown wax (71 mg, 74%); 98.0:2.0 *er*; HPLC: tR 9.04 min (major), 21.15 min (minor), 234 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Diacel AD column.



(R)-3-*iso*-Propyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3n). Light brown wax (54 mg, 56%); mp = 73 – 75 °C; $[\alpha]_D^{24}$ = –16.7 (c = 0.6, CH₂Cl₂); 98.5:1.5 *er*; HPLC: 8.16 min (minor), tR 20.83 min (major), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, ChiralCel AD column; IR (CHCl₃): 3309, 2925, 2326, 2016, 1717, 1599, 1494, 1349, 1080, 911, 749 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 7.88 (dd, J = 9.0, 1.2 Hz, 2H, ArH), 7.47 – 7.44 (m, 2H, ArH), 7.23 – 7.27 (m, 1H, ArH), 7.16 – 7.18 (m, 2H, ArH), 6.91 (t, J = 7.2 Hz, 1H), 6.56 – 6.54 (m, 2H, ArH), 4.85 (s, 1H, NH), 2.95 (hept, J = 6.9 Hz, 1H, CH), 1.48 (d, J = 6.9 Hz, 3H, CH₃), 1.32 (d, J = 6.9 Hz, 3H, CH₃); ¹³C NMR (151 MHz, CDCl₃): δ 165.0, 162.0, 142.3, 137.2, 129.9 (2C), 129.3 (2C), 126.5, 122.1, 119.2 (2C), 115.6 (2C), 112.9, 61.7, 29.6, 21.3, 19.6; MS (EI): m/z 318.0 M⁺; HRMS Calcd for [C₁₉H₁₈N₄O + Na]⁺: 341.1373, found: 341.1388.




(S)-3-*iso*-Propyl-5-oxo-1-phenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (ent-3n). Light brown wax (52 mg, 54%); 99:1.0 *er*; HPLC: tR 8.14 min (major), 21.01 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 7:3, 1.0 mL/min, Chiralpak AD column.




(R)-5-Oxo-1,3-diphenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3p). Reddish brown wax (15 mg, 14%); $[\alpha]_D^{24}$ = –20.0 (c = 0.3, CH₂Cl₂); 92.8:7.2 *er*; HPLC: tR

28.49 min (minor), 32.03 min (major), 254 nm, *n*-heptane/*i*-PrOH, 97:3, 0.5 mL/min, Chiralpak OD column; IR (CHCl₃): 3347, 3050, 2918, 2638, 2453, 2299, 2078, 1988, 1718, 1598, 1493, 1376, 1296, 1114, 909, 751, 687 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ 8.20 – 8.18 (m, 2H, ArH), 7.87 – 7.85 (m, 2H, ArH), 7.56 – 7.52 (m, 3H, ArH), 7.47 – 7.44 (m, 2H, ArH), 7.31 – 7.28 (m, 1H, ArH), 7.18 – 7.15 (m, 2H, ArH), 6.97 – 6.94 (m, 1H, ArH), 6.85 – 6.83 (m, 2H, ArH), 4.71 (s, 1H, NH); ¹³C NMR (151 MHz, CDCl₃): δ 165.1, 151.3, 141.6, 136.9, 132.2, 129.7 (2C), 129.4 (2C), 129.3 (2C), 127.9, 127.0 (2C), 126.8, 123.5, 119.5 (2C), 118.7 (2C), 113.1, 61.5; MS (ESI): *m/z* 351.9 M⁺; HRMS Calcd for [C₂₂H₁₆N₄O + H]⁺: 353.1397, found: 353.1390.





(S)-5-Oxo-1,3-diphenyl-4-(phenylamino)-4,5-dihydro-1H-pyrazole-4-carbonitrile (3p). Reddish brown wax (14 mg, 13%); 92.0:8.0 *er*; HPLC: tR 28.27 min (major), 31.91 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 97:3, 0.5 mL/min, Chiralcel OD column.





(S)-4-Amino-3-methyl-5-oxo-phenyl-4,5-dihydro-1H-pyrazole-4-carbonitrile (4). Brown wax (30 mg, 70%); [α]_D²⁴ = -11.5 (c = 0.5, CHCl₃); 96.3:3.4 *er*; HPLC: tR 6.31 min (major), 7.61 min (minor), 254 nm, *n*-heptane/*i*-PrOH, 8:2, 1.0 mL/min, Chiralpak AD column; IR (CHCl₃): 3842, 2679, 2344, 2092, 1752, 1140 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.81 – 7.79 (m, 2H, ArH), 7.43 – 7.39 (m, 2H, ArH), 7.26 – 7.22 (m, 1H, ArH), 2.32 (s, 3H, CH₃), 2.30 – 2.20 (m, 2H, NH₂); ¹³C NMR (151 MHz, CDCl₃): δ 166.1, 154.9, 136.9, 129.2 (2C), 126.4, 119.1 (2C), 114.4, 58.8, 13.6; MS (ED): *m/z* 214.2; HRMS Calcd for [C₁₁H₁₀N₄O + H]⁺: 215.0927, found: 215.0929.

NMR Spectra:


PROTON_01
e/chaohan_pc1022




CARBON_01
e/chaohan_pc1022







PROTON_01
e/Mahajan_SM214rep3





CARBON_01
e/Mahajan_SM214rep3












PROTON_01
e/Chauhan_PC1075R4




CARBON_01
e/Chauhan_PC1075R4




PROTON_01
e/mahajan_sm202




CARBON_01
e/mahajan_sm202







PROTON_01
e/Chauhan_PCKDIM-4






CARBON_01
e/Chauhan_PCKDIM-4






















PROTON_01
e/Chauhan_PC1028rep




7.846
7.842
7.837
7.834
7.831
7.437
7.419
7.415
7.400
7.397
7.298
7.295
7.239
7.223
7.220





CARBON_01
e/Chauhan_PC1028rep




184.65
149.19
144.55
136.96
129.27
126.35
117.78
11.15










PROTON_01
e/Mahajan_SM195







CARBON_01
e/Mahajan_SM195












































PROTON_01
e/chaugan_pc1110



CARBON_01
e/Chaugan_PC1109



HPLC Data:

AK Prof. Enders - Analytiklabor 4.04

RWTH AACHEN
UNIVERSITY

Sample name: **SM 226 L**

Data file: C:\SNOOPY\SM\226LIC.D



Description: Mobile phase: n-Heptane/iPrOH 97:3 ;
The sample is solved in DCM/MP

Injection date: 8/25/2016 3:36:41 PM

Acq. Analysis method: CHIRALPAKIC1-6LNP.M

Column: Chiralpak IC, (150 x 4,6) mm, 5µ, SN: IC00CD-QF015

Pressure at start: 23 bar Start flow: 0.700 ml/min Column oven: 29.98 °C



Name SM 226 L

RT [min]	Type	Area%	Area	Height	Width [min]
11.08	BV	95.49	16429.87	899.33	0.28
12.44	MM	4.51	775.52	35.74	0.36
Sum		100.00	17205.39		

AK Prof. Enders - Analytiklabor 4.04

RWTH AACHEN
UNIVERSITY

Sample name: **SM 227 L**

Data file: C:\SNOOPY\SM\227LIC.D



Description: Mobile phase: n-Heptane/iPrOH 97:3 ;
The sample is solved in DCM/MP

Injection date: 8/25/2016 3:57:49 PM

Acq. Analysis method: CHIRALPAKIC1-6LNP.M

Column: Chiralpak IC, (150 x 4,6) mm, 5µ, SN: IC00CD-QF015

Pressure at start: 23 bar Start flow: 0.700 ml/min Column oven: 29.98 °C



Name SM 227 L

RT [min]	Type	Area%	Area	Height	Width [min]
11.21	MM	6.12	953.52	52.93	0.30
12.51	BB	93.88	14637.44	723.92	0.31
Sum		100.00	15590.96		

Sample name: **SM 200**

Data file: C:\SNOOPY\SM\SM 200 IA.D


Description: Mobile phase: n-Heptane/iPrOH 7:3;
The sample is solved in DCM/MP

Injection date: 3/23/2016 8:50:39 AM

Acq. Analysis method: CHIRALPAK-IARNP.M


Column: Chiralpak IA, (250 x 4,6) mm, 5µ, SN: IA00CE-RC036

Pressure at start: 30 bar Start flow: 0.500 ml/min Column oven: 29.99 °C



Name SM 200

RT [min]	Type	Area%	Area	Height	Width [min]
7.65	BV	44.81	10882.83	1249.23	0.14
8.11	VV	55.19	13402.97	1432.66	0.15
Sum		100.00	24285.80		

Sample name: **SM2270 chiral**

Data file: C:\SNOOPY\PC\2270IA.D


Description: Mobile phase: n-Heptane/iPrOH 7:3; 0.5 ml min⁻¹ Chiralpak IA
The sample is solved in DCM/MP

Injection date: 2/3/2017 10:30:43 AM

Acq. Analysis method: CHIRALPAK-IA.M


Column: Chiralpak IA, (250 x 4,6) mm, 5µ, SN: IA00CE-RC036

Pressure at start: 30 bar Start flow: 0.500 ml/min Column oven: 30 °C



Name SM2270 chiral

RT [min]	Type	Area%	Area	Height	Width [min]
6.19	BV	0.18	41.48	3.58	0.17
6.50	VV	0.31	70.56	6.92	0.14
7.07	VB	0.45	103.95	8.20	0.18
7.71	BV	37.38	8630.44	1013.74	0.13
8.20	VB	60.24	13907.24	1514.70	0.14



Sample Name: SM226F
 Data file: D:\ERNIE\SM\226FAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 8:2



Agilent Technologies

The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 13:27:14
 Injektion Date: 17.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 36.9 35.8
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.28	0.30	14.33	284.71	3.03
2	15.32	0.58	231.55	9126.17	96.97
Total				9410.88	100.00

Sample Name: SM227F
 Data file: D:\ERNIE\SM\227FAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 8:2



Agilent Technologies

The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 13:48:15
 Injektion Date: 17.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 36.5 35.7
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.27	0.29	286.02	5715.41	96.78
2	15.32	0.57	4.93	190.26	3.22
Total				5905.67	100.00



Sample Name: SM226G
 Data file: D:\ERNIE\SM\226GAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM

Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 15:05:13
 Injektion Date: 17.08.2016

Instrument Conditions:	At Start	At Stop
Temperature in°C:	30.0	30.0
Pressure in bar:	42.2	40.8
Flow in ml/min:	1.0	1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	6.36	0.23	11.91	189.69	5.36
2	13.32	0.54	92.98	3352.00	94.64
Total				3541.69	100.00


Sample Name: SM227G
 Data file: D:\ERNIE\SM\227G2AD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM

Column: DAICELAD.M
 Column info: (250 x 4.6)mm 10µ


Operator: Analytical Lab AKEN

Injektion Time: 07:47:25
 Injektion Date: 18.08.2016

Instrument Conditions:	At Start	At Stop
Temperature in°C:	30.0	30.0
Pressure in bar:	42.0	41.1
Flow in ml/min:	1.0	1.0



->



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	6.35	0.24	1606.19	26431.27	94.42
2	13.35	0.51	45.35	1562.30	5.58
Total				27993.57	100.00

Sample name: PC-1116

Data file: C:\SNOOPY\PC\PC1116.D



Description: Mobile phase: n-Heptane/iPrOH 9:1; flow rate 1.0 ml/min
The sample is solved in DCM/MP

Injection date: 5/22/2017 10:40:51 AM

Acq. Analysis method: CHIRALPAK-IA.M

Column: Chiralpak IA, (250 x 4,6) mm, 5 μ , SN: IA00CE-RC036

Pressure at start: 44 bar Start flow: 1.000 ml/min Column oven: 30 °C



Name PC-1116

RT [min]	Type	Area%	Area	Height	Width [min]
10.35	BB	84.51	6282.66	434.16	0.22
13.81	BB	15.49	1151.75	56.98	0.31
Sum		100.00	7434.41		

Sample name: PC-1117

Data file: C:\SNOOPY\PC\PC1117.D



Description: Mobile phase: n-Heptane/iPrOH 9:1; flow rate 1.0 ml/min
The sample is solved in DCM/MP

Injection date: 5/22/2017 11:11:57 AM

Acq. Analysis method: CHIRALPAK-IA.M

Column: Chiralpak IA, (250 x 4,6) mm, 5 μ , SN: IA00CE-RC036

Pressure at start: 44 bar Start flow: 1.000 ml/min Column oven: 30 °C



Name PC-1117

RT [min]	Type	Area%	Area	Height	Width [min]
10.31	BB	11.15	1165.34	80.42	0.23
13.75	BB	88.85	9287.22	466.15	0.31
Sum		100.00	10452.56		

Sample Name: SM226H
 Data file: D:\ERNIE\SM\226HAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 08:06:24
 Injektion Date: 18.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 41.5 41.2
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.06	0.30	10.64	217.26	2.46
2	17.36	0.70	182.33	8632.19	97.54
Total				8849.45	100.00

Sample Name: SM227H
 Data file: D:\ERNIE\SM\227HAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 08:28:01
 Injektion Date: 18.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.4 41.2
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.07	0.31	831.68	17159.04	96.24
2	17.32	0.66	15.09	671.02	3.76
Total				17830.05	100.00

Sample Name: SM226J
 Data file: D:\ERNIE\SM\226JAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM





Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 09:07:35
 Injektion Date: 29.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.2 40.7
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	5.27	0.20	4.57	61.16	5.84
2	6.37	0.23	63.81	985.33	94.16
Total				1046.49	100.00

Sample Name: SM227J
 Data file: D:\ERNIE\SM\227JAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM





Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 09:22:12
 Injektion Date: 29.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 41.8 41.0
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	5.28	0.19	493.48	6335.99	91.85
2	6.37	0.23	36.13	561.87	8.15
Total				6897.86	100.00



Sample Name: SM-226E
 Data file: D:\ERNIE\SM\226EAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM

Column: DAICELAD.M
 Column info: (250 x 4.6)mm 10µ

Operator: Analytical Lab AKEN

Injektion Time: 10:31:22
 Injektion Date: 16.08.2016

Instrument Conditions:	At Start	At Stop
Temperature in°C:	30.0	30.0
Pressure in bar:	41.7	41.2
Flow in ml/min:	1.0	1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	3.60	0.21	19.67	240.35	2.27
2	8.74	0.37	11.06	257.24	2.43
3	26.88	1.16	130.16	10067.64	95.29
Total					10565.23 100.00

->



Sample Name: SM-227E
 Data file: D:\ERNIE\SM\227EAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3
 ;
 The sample is solved in DCM/LM

Column: DAICELAD.M
 Column info: (250 x 4.6)mm 10µ

Operator: Analytical Lab AKEN

Injektion Time: 11:03:35
 Injektion Date: 16.08.2016


Instrument Conditions:	At Start	At Stop
Temperature in°C:	30.0	30.0
Pressure in bar:	42.4	41.3
Flow in ml/min:	1.0	1.0




#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	3.60	0.24	27.59	410.22	3.39
2	8.70	0.39	454.51	11323.53	93.56
3	26.63	1.12	5.50	369.57	3.05
Total					12103.33 100.00

->

Sample name: SM-227N
 Data file: C:\SNOOPY\SM\227NIC.D
 Description: Mobile phase: n-Heptane/i-PrOH 8:2 ;
 The sample is solved in DCM/MP
 Injection date: 11/16/2016 2:48:46 PM
 Acq. Analysis method: CHIRALPAKIC1-6LNP.M
 Column: Chiralpak IC, (150 x 4,6) mm, 5 μ , SN: IC00CD-QF015




Pressure at start: 40 bar Start flow: 1.000 ml/min Column oven: 29.99 °C




Name SM-227N

RT [min]	Type	Area%	Area	Height	Width [min]
1.98	BV	0.49	21.75	5.15	0.07
2.10	VV	0.11	4.93	1.00	0.07
3.14	BB	3.74	166.05	29.03	0.09
3.70	BB	95.66	4243.14	614.64	0.11
Sum		100.00	4435.87		

Sample name: SM-226N
 Data file: C:\SNOOPY\SM\226NIC.D
 Description: Mobile phase: n-Heptane/i-PrOH 8:2 ;
 The sample is solved in DCM/MP
 Injection date: 11/16/2016 2:40:34 PM
 Acq. Analysis method: CHIRALPAKIC1-6LNP.M
 Column: Chiralpak IC, (150 x 4,6) mm, 5 μ , SN: IC00CD-QF015



Pressure at start: 40 bar Start flow: 1.000 ml/min Column oven: 29.99 °C



Name SM-226N

RT [min]	Type	Area%	Area	Height	Width [min]
3.14	BB	96.77	2446.97	432.07	0.09
3.70	BB	3.23	81.56	11.27	0.11
Sum		100.00	2528.53		

Sample Name: SM-226D
 Data file: D:\ERNIE\SM\226DRAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3



The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4.6)mm 10µ

Operator: Analytical Lab AKEN

Injektion Time: 08:47:57
 Injektion Date: 16.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.1 41.2
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	11.86	0.46	18.06	579.71	3.00
2	43.87	1.66	144.35	18747.02	97.00
Total				19326.73	100.00

->

Sample Name: SM-227D
 Data file: D:\ERNIE\SM\227DRAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3



The sample is solved in DCM/LM


Column: DAICELAD.M
 Column info: (250 x 4.6)mm 10µ

Operator: Analytical Lab AKEN


Injektion Time: 09:39:22
 Injektion Date: 16.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 41.8 41.4
 Flow in ml/min: 1.0 1.0



->



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	11.84	0.48	104.49	3366.11	95.76
2	43.18	2.12	1.17	149.08	4.24
Total				3515.19	100.00

Sample Name: SM 226 K
 Data file: D:\ERNIE\SM\226KAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM





Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN

Injektion Time: 13:15:39
 Injektion Date: 23.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 41.4 41.3
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.76	0.16	184.84	2007.76	96.62
2	5.86	0.21	4.86	70.34	3.38
Total					100.00

Sample Name: SM 227 K
 Data file: D:\ERNIE\SM\227KAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM





Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN

Injektion Time: 13:39:50
 Injektion Date: 23.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 43.1 41.5
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.77	0.18	4.94	59.42	2.69
2	5.86	0.21	151.68	2150.16	97.31
Total					100.00

Sample Name: SM226I
 Data file: D:\ERNIE\SM\226IAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM




Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN


Injektion Time: 08:10:33
 Injektion Date: 29.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 41.6 40.8
 Flow in ml/min: 1.0 1.0



->



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.54	0.22	4.49	67.90	0.77
2	8.03	0.30	14.65	303.77	3.44
3	20.72	0.00	1.92	0.00	0.00
4	21.64	1.02	138.27	8460.10	95.79
5	22.00	0.00	90.66	0.00	0.00
6	22.56	0.00	28.71	0.00	0.00
7	22.96	0.00	11.74	0.00	0.00
8	23.52	0.00	2.51	0.00	0.00
Total				8831.76	100.00

Sample Name: SM227I
 Data file: D:\ERNIE\SM\227IAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3 ;
 The sample is solved in DCM/LM




Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN


Injektion Time: 08:40:24
 Injektion Date: 29.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.1 41.1
 Flow in ml/min: 1.0 1.0



->



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	4.54	0.29	3.58	62.59	0.64
2	4.73	0.00	1.69	0.00	0.00
3	8.02	0.32	436.25	9272.51	94.81
4	21.61	0.00	7.01	0.00	0.00
5	21.65	1.04	7.12	445.50	4.55
6	22.90	0.00	0.96	0.00	0.00
Total				9780.60	100.00

Sample Name: SM226m
 Data file: D:\ERNIE\SM\226MAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 8:2 ;
 The sample is solved in DCM/LM





Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN


Injektion Time: 14:25:36
 Injektion Date: 29.08.2016

Instrument Conditions:	At Start	At Stop
Temperature in °C:	30.0	30.0
Pressure in bar:	36.4	35.3
Flow in ml/min:	1.0	1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	9.04	0.32	6.46	142.21	1.89
2	21.19	0.81	132.58	7366.34	98.11
Total					7508.54 100.00

Sample Name: SM227m
 Data file: D:\ERNIE\SM\227MAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 8:2 ;
 The sample is solved in DCM/LM




Column: DAICELAD.M
 Column info: Chiralpak AD (250 x 4.6)mm 10μ

Operator: Analytical Lab AKEN

Injektion Time: 15:00:29
 Injektion Date: 29.08.2016

Instrument Conditions:	At Start	At Stop
Temperature in °C:	30.0	30.0
Pressure in bar:	36.4	35.7
Flow in ml/min:	1.0	1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	3.26	0.15	2.58	28.12	1.66
2	3.65	0.15	2.16	22.59	1.33
3	4.48	0.18	1.11	13.78	0.81
4	9.04	0.32	73.00	1598.09	94.19
5	21.15	0.86	0.66	34.12	2.01
Total					1696.69 100.00

Sample Name: SM-226C
 Data file: D:\ERNIE\SM\226CRAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3



The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 12:39:19
 Injektion Date: 15.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.8 41.6
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.16	0.31	14.01	287.26	1.57
2	20.83	0.89	301.06	17962.86	98.43
Total				18250.12	100.00

Sample Name: SM-227C
 Data file: D:\ERNIE\SM\227CAD.D
 Sample Info: Mobile phase: n-Heptane/iPrOH 7:3



The sample is solved in DCM/LM



Column: DAICELAD.M
 Column info: (250 x 4)mm; 5µ non-chiral column

Operator: Analytical Lab AKEN

Injektion Time: 13:15:28
 Injektion Date: 15.08.2016

Instrument Conditions: At Start At Stop

Temperature in °C: 30.0 30.0
 Pressure in bar: 42.2 41.6
 Flow in ml/min: 1.0 1.0



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	8.14	0.32	520.11	11039.21	98.92
2	21.01	0.71	2.25	120.06	1.08
Total				11159.27	100.00


Sample Name: SM-226B
 Data file: F:\2016#PNI.19D\SM\226BOD.D
 Sample Info: Mobile phase: n-Heptane/EtOH 97:3;
 The sample is solved in DCM/MP




Säule: DAICELOD.M
 Säuleninfo: Chiralpak AD (250x4,6)mm
 Operator: Analytik Labor AKEN

Injektion Time: 13:11:45
 Injektion Date: 25.11.2016

Instrument Conditions: At Start At Stop
 Temperature in °C: 30.0 °C 30.0 °C
 Pressure in bar: 19.1 18.9
 Flow in ml/min: 0.50 0.50



(R)-3p



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	28.49	0.87	1.56	114.20	7.30
2	32.03	1.16	17.09	1450.54	92.70
Total				1564.74	100.00


Sample Name: SM-227B
 Data file: F:\2016#PNI.19D\SM\227BOD.D
 Sample Info: Mobile phase: n-Heptane/EtOH 97:3;
 The sample is solved in DCM/MP




Säule: DAICELOD.M
 Säuleninfo: Chiralpak AD (250x4,6)mm
 Operator: Analytik Labor AKEN

Injektion Time: 14:02:58
 Injektion Date: 25.11.2016

Instrument Conditions: At Start At Stop
 Temperature in °C: 30.0 °C 30.0 °C
 Pressure in bar: 19.2 19.3
 Flow in ml/min: 0.50 0.50



(S)-3p



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	28.27	1.12	51.32	4021.58	93.71
2	31.92	1.28	3.51	269.72	6.29
Total				4291.30	100.00



Sample Name: PC1110RAC
 Data file: D:\GONZO\PC\PC1110RA.D
 Sample Info: Chiralpak AD, 8:2 (Heptan:IPROH), 1 ml min⁻¹
 The sample is solved in DCM/MP



Säule: DAICELAD.M
 Säuleninfo: Chiralpak AD (250x4,6)mm
 Operator: Analytik Labor AKEN

Injektion Time: 15:49:55
 Injektion Date: 09.03.2017

Instrument Conditions: At Start At Sto
 Temperature in °C: 30.0°C 30.0
 Pressure in bar: 35.6 35.8
 Flow in ml/min: 1.00 1.00



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	6.30	0.26	26.35	465.24	36.03
2	6.89	0.22	2.07	36.19	2.80
3	7.55	0.31	37.92	789.87	61.17
Total				1291.31	100.00



Sample Name: PC1112
 Data file: D:\GONZO\PC\PC1112.D
 Sample Info: n-Heptane/iPrOH 8:2; Flow= 1.0 ml min⁻¹, Chiralpak AD
 The sample is solved in DCM/MP



Säule: DAICELAD.M
 Säuleninfo: Chiralpak AD (250x4,6)mm
 Operator: Analytik Labor AKEN

Injektion Time: 10:17:46
 Injektion Date: 03.04.2017

Instrument Conditions: At Start At Sto
 Temperature in °C: 30.0°C 30.0
 Pressure in bar: 33.3 33.3
 Flow in ml/min: 1.00 1.00



#	Ret. Time (min)	Width	Height (mAU)	Area (mAU*s)	Area %
1	6.32	0.28	51.67	990.34	96.80
2	7.61	0.32	1.32	32.78	3.20
Total				1023.13	100.00